Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

BeOne Medicines (BEIGF) Long-Term Debt Repayments (2019 - 2025)

Historic Long-Term Debt Repayments for BeOne Medicines (BEIGF) over the last 4 years, with Q3 2025 value amounting to $4.3 million.

  • BeOne Medicines' Long-Term Debt Repayments rose 1971.36% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.5 million, marking a year-over-year increase of 3815.6%. This contributed to the annual value of $28.0 million for FY2024, which is 10475.53% up from last year.
  • According to the latest figures from Q3 2025, BeOne Medicines' Long-Term Debt Repayments is $4.3 million, which was up 1971.36% from $12.6 million recorded in Q2 2025.
  • Over the past 5 years, BeOne Medicines' Long-Term Debt Repayments peaked at $12.6 million during Q2 2025, and registered a low of -$1.5 million during Q2 2023.
  • Moreover, its 3-year median value for Long-Term Debt Repayments was $4.3 million (2025), whereas its average is $5.7 million.
  • Over the last 5 years, BeOne Medicines' Long-Term Debt Repayments had its largest YoY gain of 81660.95% in 2024, and its largest YoY loss of 5791.77% in 2024.
  • Over the past 3 years, BeOne Medicines' Long-Term Debt Repayments (Quarter) stood at $5.2 million in 2023, then skyrocketed by 99.89% to $10.4 million in 2024, then plummeted by 59.21% to $4.3 million in 2025.
  • Its Long-Term Debt Repayments was $4.3 million in Q3 2025, compared to $12.6 million in Q2 2025 and $4.2 million in Q1 2025.